Several FABP4 inhibitors have been shown to be effective in alleviating chronic inflammatory disorders, including insulin resistance, atherosclerosis, nonalcoholic fatty liver disease, and osteoarthritis (17, 18, 46). Here, FABP4 is linked to metabolic dysfunction-associated steatotic liver disease.